Chikungunya -- Brazil
Key points
----------
Question: What is the safety and tolerability of a chikungunya virus-like particle vaccine (CHIKV VLP) in a chikungunya endemic area?
Findings: In this randomized clinical trial that included 400 healthy adults in 6 Caribbean sites, CHIKV VLP compared with placebo did not result in a significantly increased risk of clinically important adverse events.
Meaning: In this phase 2 trial, a chikungunya virus-like particle vaccine appeared to be safe and well-tolerated,
Read more about it at HealthMap Global Disease Alerts via http://healthmap.org/ln.php?7454688&promed&0
No comments:
Post a Comment